SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Alembic Pharmaceuticals Ltd

BSE: 533573 NSE: APLLTD ISIN: INE901L01018
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Alembic Pharmaceuticals Ltd belong to?
Alembic Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Alembic Pharmaceuticals Ltd a good quality company?
Alembic Pharmaceuticals Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Alembic Pharmaceuticals Ltd undervalued or overvalued?
Alembic Pharmaceuticals Ltd appears Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Alembic Pharmaceuticals Ltd a good buy now?
Alembic Pharmaceuticals Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd revenue growth is 7.1% for FY-2025 , which is below its 5 year CAGR of 7.7% , indicating slower growth.
Q.2 Gross Profit margin of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 14.6% for FY-2025 , which is in line with its 5 year median of 14.6% , indicating stable margins.
Q.3 Operating Profit Margin of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 15.03% for FY-2025 , which is in line with its 5 year median of 15.03% indicating stable margins.
Q.4 Net Profit Margin of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd Net Profit Margin is 8.72% for FY-2025 , is below with its 5 year median of 9.82%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 14.6 14.6
Operating Profit Margin 15.03 15.03
Net Profit Margin 8.72 9.82
Q.5 Return on Asset of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd Return on Asset is 8.28%, which is in line with its 5 year historical median of 8.28%, indicating stable asset utilization efficiency.
Q.6 Return on Equity (ROE) of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd Return on equity is 11.63% for FY-2025 , which is in line with its historical median of 11.63%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd Return on capital employed is 13.51% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 13.5%, indicating value creation.
Q.8 Cash conversion cycle of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd Cash conversion cycle is 121 days, above its historical median of 102 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.95 0.85
ROE 11.63 11.63
ROCE 13.51 13.42
Cash Conversion Cycle 121 days 102 days
Q.9 Debt to Equity ratio of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd Debt-to-Equity ratio is 0.23 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd Debt to cash flow from operations is 13.59 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Alembic Pharmaceuticals Ltd?
Promoters hold 69.74% of the Alembic Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Alembic Pharmaceuticals Ltd vs industry peers?
Alembic Pharmaceuticals Ltd revenue CAGR is 7.69% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 6,672.1 137.1
Gross Profit 974.1 15.1
Operating Profit 1,003 16
Net Profit 582 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.95 0.8
ROE 11.63 8.91
ROCE 13.51 11.59
Cash Conversion Cycle (days) 121.03 76

Valuation & price assessment

Q.1 Stock return of Alembic Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 3.4% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 3.4% -4.7% 13.9% -7.7%
Q.3 Valuation ratios of Alembic Pharmaceuticals Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 23.41 19.34 40.28
Price to Book 2.7 4.57 2.77
Price to Sales 2.03 0.00 2.65
EV to EBITDA 13.26 15.01 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×